Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations

IF 11.1 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-09-10 DOI:10.1002/alz.70348

Margaret M. Weden, Lori Frank, Andrew W. Dick, Zetianyu Wang, Susan Peschin, Diane E. Bovenkamp, Sharyn L. Rossi, Dana Sciullo, Hampus Hillerstrom, Richard A. Fisher

{"title":"Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations","authors":"Margaret M. Weden, Lori Frank, Andrew W. Dick, Zetianyu Wang, Susan Peschin, Diane E. Bovenkamp, Sharyn L. Rossi, Dana Sciullo, Hampus Hillerstrom, Richard A. Fisher","doi":"10.1002/alz.70348","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Recent innovations in Alzheimer's disease (AD) treatment highlight critical gaps in knowledge about how to support healthy aging of adults with Down syndrome (DS). RAND researchers updated demographic and epidemiological evidence about the DS population to assess the impact of increased investment in treatment innovations for DS-associated Alzheimer's disease (DS-AD). They estimated life expectancy at birth in 2020 to be 55 years, with ≈ 5 years of DS-AD. They found that the results of investment were dramatic. Between 2020 and 2070, adult years of life are expected to increase by 5 years without any increase in unhealthy years of life with DS-AD. Caregiving hours for individuals with DS-AD are expected to be reduced by 40%, which will generate large annual savings. The new evidence underscores the magnitude of the impact that investment in DS-AD treatments could have for individuals with DS, their families, and caregivers.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Evidence is sparse about treatment for Down syndrome (DS)-associated Alzheimer's disease (DS-AD) and healthy aging of DS adults.</li>\n \n <li>This population simulation model estimates DS-AD caregiving costs at ≈ $1 billion per year.</li>\n \n <li>DS-AD innovations could increase life expectancy by 5 years and reduce caregiving by 40% by 2070.</li>\n \n <li>This better forecasting can improve policy and service planning.</li>\n \n <li>DS-AD research investment could yield dramatic gains for individuals and families.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70348","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70348","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent innovations in Alzheimer's disease (AD) treatment highlight critical gaps in knowledge about how to support healthy aging of adults with Down syndrome (DS). RAND researchers updated demographic and epidemiological evidence about the DS population to assess the impact of increased investment in treatment innovations for DS-associated Alzheimer's disease (DS-AD). They estimated life expectancy at birth in 2020 to be 55 years, with ≈ 5 years of DS-AD. They found that the results of investment were dramatic. Between 2020 and 2070, adult years of life are expected to increase by 5 years without any increase in unhealthy years of life with DS-AD. Caregiving hours for individuals with DS-AD are expected to be reduced by 40%, which will generate large annual savings. The new evidence underscores the magnitude of the impact that investment in DS-AD treatments could have for individuals with DS, their families, and caregivers.

Highlights

Evidence is sparse about treatment for Down syndrome (DS)-associated Alzheimer's disease (DS-AD) and healthy aging of DS adults.
This population simulation model estimates DS-AD caregiving costs at ≈ $1 billion per year.
DS-AD innovations could increase life expectancy by 5 years and reduce caregiving by 40% by 2070.
This better forecasting can improve policy and service planning.
DS-AD research investment could yield dramatic gains for individuals and families.

Abstract Image

查看原文本刊更多论文

对患有唐氏综合症的下一代成年人的阿尔茨海默病研究的投资将为子孙后代带来健康益处

阿尔茨海默病（AD）治疗的最新创新凸显了如何支持患有唐氏综合症（DS）的成年人健康老龄化的知识缺口。兰德研究人员更新了有关DS人群的人口学和流行病学证据，以评估增加对DS相关阿尔茨海默病（DS- ad）治疗创新投资的影响。他们估计2020年出生时的预期寿命为55岁，其中DS-AD约为5年。他们发现投资的结果是惊人的。2020年至2070年期间，预计患有DS-AD的成人寿命将增加5年，而不健康寿命不会增加。预计DS-AD患者的护理时间将减少40%，这将每年节省大量费用。新的证据强调了对DS- ad治疗的投资可能对DS患者、他们的家庭和照顾者产生的巨大影响。关于唐氏综合征（DS）相关阿尔茨海默病（DS- ad）治疗和DS成人健康老龄化的证据很少。这个人口模拟模型估计，DS-AD护理成本每年约为10亿美元。到2070年，DS-AD创新可以将预期寿命延长5年，并将护理减少40%。这种更好的预测可以改善政策和服务规划。DS-AD研究投资可以为个人和家庭带来巨大收益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.